When was VERAXA founded?

VERAXA was founded in 2017 and raised its 1st funding round 2 years after it was founded.

Where is VERAXA located?

VERAXA is headquartered in Heidelberg, Germany.

Which legal entities is VERAXA associated with?

VERAXA is associated with Velabs Therapeutics GmbH and 1 other.

How many employees does VERAXA have?

As of Jun 30, 2026, the latest employee count at VERAXA is 47.

Is VERAXA a funded company?

VERAXA is a funded company, having raised a total of $***** in its 1st and only funding round, a Series B round on Jun 27, 2019.

When was the latest funding round of VERAXA?

VERAXA's latest funding was a $***** Series B round on Jun 27, 2019, with participation from 0 investor.

Where does VERAXA rank among its competitors?

VERAXA ranks 57th amongst 410 active competitors, of which 154 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Cue Biopharma, which secured $50M in Jul, 2026.

Who are the top competitors of VERAXA?

VERAXA's top competitors include Abcellera Biologics, Agios Pharmaceuticals and TScan Therapeutics. Among them, Cue Biopharma secured the most recent funding round in July, 2026.

VERAXA - 2026 Company Profile, Team, Funding & Competitors

VERAXA is a series B company based in Heidelberg (Germany), founded in 2017 by Edward A. Lemke, Christoph A. Merten and Edward Lemke. It operates as a Developer of antibody therapeutics for cancer treatment. VERAXA has raised $3.41M in funding. The company has 410 active competitors, including 154 funded and 85 that have exited. Its top competitors include companies like Abcellera Biologics, Agios Pharmaceuticals and TScan Therapeutics.

Company Details

Developer of antibody therapeutics for cancer treatment. The company is focusing on ADC engineering and functional antibody screening for the treatment of oncological conditions. The company’s droplet-based microfluidic screening technology and its innovative antibody and protein conjugation technology allow for a rapid generation of antibodies against the most complex target molecules.

Website: veraxa.com
Email ID: *****@veraxa.com
Phone Number: +49 **********

Key Metrics

Founded Year

2017

Location

Heidelberg, Germany

Stage

Series B

Total Funding

$3.41M in 1 round

Latest Funding Round

Series B, Jun 27, 2019, $*****

Ranked

57^th among 410 active competitors

Employee Count

47 as on Jun 30, 2026

Investment & Acquisitions

SYNIMMUNE

Similar Companies

Abcellera Biologics & 515 more

View VERAXA's full profile

VERAXA is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
VERAXA Biotech GmbH CIN: HRB740261 , Germany, Active	Dec 31, 2020	-	-
Velabs Therapeutics GmbH CIN: HRB235981 , Germany, Active	Sep 21, 2017	-	-

VERAXA has raised a total funding of $3.41M over 1 round.

Here is the list of recent funding rounds of VERAXA:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 27, 2019	2877089	Series B	8208251	1490604	1181035	7894113

Access funding benchmarks and valuations. Sign up today!

View details of VERAXA's funding rounds and investors

The founders of VERAXA are Edward A. Lemke, Christoph A. Merten and Edward Lemke.

Here are the details of VERAXA's key team members:

Edward A. Lemke: Co-Founder of VERAXA.
Christoph A. Merten: Co-Founder of VERAXA.
Edward Lemke: Co-Founder And Consultant of VERAXA.

View details of VERAXA's Founder profiles and Board Members

VERAXA's employee count trend

VERAXA has 47 employees as of Jun 26. Here is VERAXA's employee count trend over the years:

Uncover VERAXA's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of VERAXA include Abcellera Biologics, Agios Pharmaceuticals and TScan Therapeutics. Here is the list of Top 10 competitors of VERAXA, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	71/100
2nd	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Arch Venture Partners, Flagship Pioneering ... & 6 others	70/100
3rd	TScan Therapeutics 1995, Boston (United States), Public	Developer of T cell therapies to harness the immune system against cancer	$180M	RA Capital Management, Novartis & 9 others	70/100
4th	Beijing Jiakesi drug development 2015, Beijing (China), Public	Developer of small molecule based therapeutics for cancer treatment	$55M	Qiming Venture Partners, Lilly Asia Ventures ... & 3 others	67/100
5th	Cue Biopharma 2015, Cambridge (United States), Public	Precision immunotherapies to transform patients' lives by selectively modulating the immune system	$26.4M	MDB Capital	64/100
6th	Lyell Immunopharma 2018, San Francisco (United States), Public	Developer of CAR- T therapy for cancer treatment	$493M	Sahsen Ventures, GSK & 5 others	63/100
7th	ABL Bio 2016, Seongnam-si (South Korea), Public	Bi-specific antibodies and Antibody-drug Conjugate immunotherapies for oncology and neurodegenerative diseases	$65M	QUAD, Hana Financial Group & 7 others	63/100
8th	Cumulus Oncology 2017, Edinburgh (United Kingdom), Seed	Developer of therapies for treating cancers	$19.2M	Eos Advisory, Scottish Investment Bank & 26 others	61/100
9th	Black Diamond Therapeutics 2017, Cambridge (United States), Public	Developing MasterKey therapies to defeat cancer resistance and improve patient lives	$207M	Boxer Capital, RA Capital Management & 19 others	61/100
10th	Boundless Bio 2018, San Diego (United States), Public	Developer of therapeutics for cancer by targeting ecDNA	$252M	RA Capital Management, Bayer & 19 others	61/100
57th	VERAXA 2017, Heidelberg (Germany), Series B	Developer of antibody therapeutics for cancer treatment	$3.41M	-	53/100